TABLE 2.
In vitro susceptibilities of Candida spp. to fluconazole and voriconazole as determined by CLSI disk diffusion method
| Species | Fluconazolea |
Voriconazolea |
Cross-resistant |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
| S |
R |
S/WT |
R/NWT |
|||||||
| No. | % | No. | % | No. | % | No. | % | No. | % | |
| C. albicans | 3,927 | 99.0 | 20 | 0.5 | 3,928 | 99.1 | 30 | 0.8 | 19 | 0.5 |
| C. parapsilosis complex | 1,600 | 90.8 | 94 | 5.3 | 1,710 | 97.0 | 44 | 2.5 | 44 | 2.5 |
| C. parapsilosis sensu stricto | 1,425 | 93.4 | 61 | 4.0 | 1,485 | 97.3 | 34 | 2.2 | 34 | 2.2 |
| C. metapsilosis | 117 | 70.1 | 23 | 13.8 | 166 | 99.4 | 1 | 0.6 | 1 | 0.6 |
| C. orthopsilosis | 24 | 68.6 | 10 | 28.6 | 25 | 71.4 | 9 | 25.7 | 9 | 25.7 |
| L. elongisporus | 34 | 100 | 34 | 100 | ||||||
| C. tropicalis | 1,285 | 84.8 | 202 | 13.3 | 1,295 | 85.5 | 200 | 13.2 | 195 | 12.9 |
| C. glabrata complex | 179 | 18.7 | 814 | 85.2 | 141 | 14.8 | 134 | 14.0 | ||
| C. glabrata sensu stricto | 179 | 19.0 | 800 | 85.0 | 141 | 15.0 | 134 | 14.2 | ||
| C. nivariensis | 13 | 100 | ||||||||
| C. bracarensis | 1 | 100 | ||||||||
| C. guilliermondii | 71 | 38.2 | 54 | 29.0 | 157 | 84.4 | 23 | 12.4 | 23 | 12.4 |
| C. krusei | 125 | 100 | 118 | 94.4 | 4 | 3.2 | 4 | 0.3 | ||
| C. pelliculosa | 68 | 55.3 | 24 | 19.5 | 102 | 82.9 | 12 | 9.8 | 12 | 9.8 |
| C. lusitaniae | 48 | 96.0 | 50 | 100 | ||||||
| C. lipolytica | 6 | 16.7 | 25 | 69.4 | 24 | 66.7 | 12 | 33.3 | 12 | 33.3 |
| C. haemulonii | 5 | 20.8 | 18 | 75.0 | 15 | 62.5 | 9 | 37.5 | 9 | 37.5 |
| C. intermedia | 18 | 90.0 | 2 | 10.0 | 20 | 100 | ||||
| C. norvegensis | 3 | 23.1 | 7 | 53.8 | 13 | 100 | ||||
| C. fabianii | 11 | 100 | 11 | 100 | ||||||
| C. inconspicua | 1 | 12.5 | 7 | 87.5 | 8 | 100 | ||||
| C. rugosa | 3 | 42.9 | 4 | 57.1 | 7 | 100 | ||||
| C. fermentati | 4 | 66.7 | 2 | 33.3 | 6 | 100 | ||||
| C. catenulata | 3 | 75.0 | 1 | 25.0 | 3 | 75.0 | 3 | 75.0 | ||
| C. quercitrusa | 3 | 75.0 | 4 | 100 | ||||||
| C. aaseri | 2 | 66.7 | 3 | 100 | ||||||
| C. kefyr | 3 | 100 | 3 | 100 | ||||||
| C. famata | 2 | 66.7 | 1 | 33.3 | 3 | 100 | ||||
| C. magnoliae | 1 | 100 | 1 | 100 | ||||||
| C. utilis | 1 | 100 | 1 | 100 | ||||||
| C. diddensiae | 1 | 100 | 1 | 100 | 1 | 100 | ||||
| C. palmioleophila | 1 | 100 | 1 | 100 | 1 | 100 | ||||
| C. opuntiae | 1 | 100 | 1 | 100 | ||||||
| C. freyschussii | 1 | 100 | 1 | 100 | ||||||
| Total | 7,059 | 80.0 | 774 | 8.8 | 8,296 | 94.0 | 480 | 5.4 | 457 | 5.2 |
a
Species-specific MIC clinical breakpoint (CBP) interpretive criteria were applied to C. albicans, Candida tropicalis, the C. parapsilosis complex, the Candida glabrata complex, and Candida krusei according to the guidelines in the reference CLSI M60 document (17), and the susceptibilities of the other Candida species were interpreted in accordance with CLSI M44-S3 document guidelines (18). S, susceptible; WT, wild type; R, resistant; NWT, non-wild type.